Reach Us +1-504-608-2390
The Link Between Oral Contraceptive Use And Prevalence In Autism Spectrum Disorder | 32014
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The link between oral contraceptive use and prevalence in autism spectrum disorder

4th Global Summit on Toxicology

Kim Strifert

ScientificTracks Abstracts: J Clin Toxicol

DOI: 10.4172/2161-0495.S1.015


It is now estimated that 1 in 68 children are diagnosed with ASD in the United States. So far, no definitive cause or contributing
factors have been established to account for the increase in prevalence in ASD. Combined oral contraceptive (COC) use is one
possible risk factor for the increase in prevalence that has been overlooked in the existing biomedical and epidemiologic literature.
One of the compounds found in combined oral contraceptives (COCs) is the synthetic estrogen Ethinylestradiol (EE2). EE2 is a
known endocrine disrupting compound (EDC) capable of causing harmful effects to the endocrine system and to progeny. Since
COCs were developed to mimic natural human hormones and disrupt endogenous endocrine function to prevent pregnancy, there is
reason for concern that the EE2 component may be associated with the adverse neurodevelopmental effects that lead to the increase
in ASDs. This hypothesis is compelling due to several considerations. As the prevalence of COC use has risen over the last fifty years
so has the prevalence of ASDs. As a category of agents there are specific documented mechanisms through which COCs can affect the
oocyte and/or developing embryo. As COCs are taken deliberately, exposure occurs at pharmacologically effective concentrations.
The possibility exists that the effects of COC use could intensify over generations due to transgenerational transmission of altered
epigenetic programming, with continued exposure across generations imparting sensitivity to developing ASDs. Lastly, the specific
demographic at risk, women who are likely to have children, is the exact demographic that is taking COCs.


Kim Strifert was previously employed as a healthcare administrator at the Mayo Clinic, the Department of Obstetrics and Gynecology and the Office of Academic Analytic
Support at Baylor College of Medicine. She is currently affiliated with the Graduate School, School of Public Health, at the University of Alabama at Birmingham. Her
recent article, “The link between oral contraceptive use and the increase in the prevalence of autism spectrum disorder” is available through the Elsevier Journal Medical
Hypotheses. The article is of significance to all women and their families as it hypothesizes that the increase in the occurrence of autism coincides with the increase in the
use of hormonal contraceptives. It is important because it identifies the lack of medical research into the neurodevelopmental effects of oral contraceptive use on offspring
and calls for further research.